Rheumatoid Arthritis - Pipeline Review, H2 2011

Global Markets Direct, September 2011, Pages: 218

Rheumatoid Arthritis - Pipeline Review, H2 2011

Summary

Global Markets Direct’s, 'Rheumatoid Arthritis - Pipeline Review, H2 2011', provides an overview of the Rheumatoid Arthritis therapeutic pipeline. This report provides information on the therapeutic development for Rheumatoid Arthritis, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Rheumatoid Arthritis. 'Rheumatoid Arthritis - Pipeline Review, H2 2011' is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note-: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Rheumatoid Arthritis.
- A review of the Rheumatoid Arthritis products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Rheumatoid Arthritis pipeline on the basis of route of administration and molecule type.
- Profiles of late-stage pipeline products featuring sections on product description, mechanism of action and research & development progress.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Rheumatoid Arthritis.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players with the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Rheumatoid Arthritis pipeline depth and focus of Rheumatoid Arthritis therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.

List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Rheumatoid Arthritis Overview
Therapeutics Development
An Overview of Pipeline Products for Rheumatoid Arthritis
Rheumatoid Arthritis Therapeutics under Development by Companies
Rheumatoid Arthritis Therapeutics under Investigation by Universities/Institutes
Late Stage Products
Comparative Analysis
Mid Clinical Stage Products
Comparative Analysis
Early Clinical Stage Products
Comparative Analysis
Discovery and Pre-Clinical Stage Products
Comparative Analysis
Rheumatoid Arthritis Therapeutics - Products under Development by Companies
Rheumatoid Arthritis Therapeutics - Products under Investigation by Universities/Institutes
Companies Involved in Rheumatoid Arthritis Therapeutics Development
Bristol-Myers Squibb Company
Angiotech Pharmaceuticals, Inc.
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Biogen Idec Inc.
Amgen Inc.
AstraZeneca PLC
Eli Lilly and Company
GlaxoSmithKline plc
Genentech, Inc.
Palau Pharma S.A
Philogen S.p.A.
Probiodrug AG
Neovacs SA
MIKA Pharma GmbH
CREABILIS Therapeutics S.r.l.
MAT Biopharma
Lycera Corp.
OHR Pharmaceutical Inc.
Femta Pharmaceuticals, Inc.
UCB S.A.
Mycenax Biotech Inc.
Cellmid Ltd
Mebiopharm Co., Ltd.
Rheumatoid Arthritis - Therapeutics Assessment
Assessment by Monotherapy Products
Assessment by Combination Products
Assessment by Route of Administration
Assessment by Molecule Type
Late Stage Drug Profiles
REGN88 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
MAbThera - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LY2127399 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
CP-690550 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arzerra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Actemra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Cimzia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Arcoxia - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-614 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Iguratimod - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Lodotra - Drug Profile
Product Description
Mechanism of Action
R&D Progress
LT-NS001 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
AB1010 - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Leflunomide - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Prednisone - Drug Profile
Product Description
Mechanism of Action
R&D Progress
T-614 + Methotrexate - Drug Profile
Product Description
Mechanism of Action
R&D Progress
Rheumatoid Arthritis Therapeutics – Drug Profile Updates
Rheumatoid Arthritis Therapeutics - Discontinued Products
Rheumatoid Arthritis - Featured News
Sep 06, 2011: Vertex Announces Positive Phase IIa Study Results Of VX-509 In Rheumatoid Arthritis
Aug 10, 2011: NICE Asks For More Information On Use Of Tocilizumab For Systemic Juvenile Idiopathic Arthritis
Aug 10, 2011: Glenmark Initiates Phase IIb Human Trials Globally For Revamilast
Aug 03, 2011: AB Science Announces Recruitment Of First Patient In Phase IIB/III Study Of Masitinib In Rheumatoid Arthritis
Aug 03, 2011: Roche Receives European Approval For Use Of RoACTEMRA For Treatment Of Active Systemic Juvenile Idiopathic Arthritis
Aug 03, 2011: Dynamix reports new Preclinical Data for DNX-04042 Supporting Development in Rheumatoid Arthritis
Aug 01, 2011: Femta Pharmaceuticals Announces IND Filing Of FM101
Jul 29, 2011: Bristol-Myers Squibb Receives FDA Approval For Subcutaneous Formulation Of ORENCIA For Treatment Of Adults With Moderate To Severe Rheumatoid Arthritis
Jul 22, 2011: FDA Issues Complete Response Letter To Janssen Biotech For SIMPONI sBLA
Jun 29, 2011: Zalicus Initiates Phase IIb Clinical Trial Of Synavive In Rheumatoid Arthritis
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer

List of Tables
Number of Products Under Development for Rheumatoid Arthritis, H2 2011
Products under Development for Rheumatoid Arthritis – Comparative Analysis, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Development by Companies, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Number of Products under Investigation by Universities/Institutes, H2 2011
Comparative Analysis by Late Stage Development, H2 2011
Comparative Analysis by Mid Clinical Stage Development, H2 2011
Comparative Analysis by Early Clinical Stage Development, H2 2011
Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Bristol-Myers Squibb Company, H2 2011
Angiotech Pharmaceuticals, Inc., H2 2011
Johnson & Johnson, H2 2011
Boehringer Ingelheim GmbH, H2 2011
F. Hoffmann-La Roche Ltd., H2 2011
Biogen Idec Inc., H2 2011
Amgen Inc., H2 2011
AstraZeneca PLC, H2 2011
Eli Lilly and Company, H2 2011
GlaxoSmithKline plc, H2 2011
Genentech, Inc., H2 2011
Inovio Biomedical Corporation, H2 2011
MedImmune LLC, H2 2011
Biotest AG, H2 2011
Alkermes, Inc., H2 2011
Daiichi Sankyo Company, Ltd, H2 2011
Merck & Co., Inc., H2 2011
Santen Pharmaceutical Co., Ltd., H2 2011
Ablynx, H2 2011
Emergent BioSolutions Inc., H2 2011
Micromet, Inc., H2 2011
Myriad Genetics, Inc., H2 2011
Novo Nordisk A/S, H2 2011
Infinity Pharmaceuticals, Inc., H2 2011
Takeda Pharmaceutical Company Limited, H2 2011
BioLineRx, Ltd., H2 2011
arGentis Pharmaceuticals, LLC, H2 2011
Symphogen A/S, H2 2011
MediGene AG, H2 2011
Celltrion, Inc., H2 2011
Nycomed International Management GmbH, H2 2011
Pacira Pharmaceuticals, Inc., H2 2011
Novartis AG, H2 2011
Biocon Limited, H2 2011
Daewoong Pharmaceutical Co., Ltd., H2 2011
Dong-A Pharmaceutical Co., Ltd., H2 2011
Eisai Co., Ltd., H2 2011
Glenmark Pharmaceuticals Ltd., H2 2011
Maxygen, Inc., H2 2011
Mitsubishi Tanabe Pharma Corporation, H2 2011
Pfizer Inc., H2 2011
Rigel Pharmaceuticals, Inc., H2 2011
Santarus, Inc., H2 2011
Teva Pharmaceutical Industries Limited, H2 2011
Toyama Chemical Co. Ltd, H2 2011
Vertex Pharmaceuticals Incorporated, H2 2011
Warner Chilcott Limited, H2 2011
Zydus Cadila Healthcare Limited, H2 2011
Genmab A/S, H2 2011
Exelixis, Inc., H2 2011
Paratek Pharmaceuticals, Inc., H2 2011
CEL-SCI Corporation, H2 2011
AVI BioPharma Inc., H2 2011
Celgene Corporation, H2 2011
Onyx Pharmaceuticals, Inc., H2 2011
Incyte Corporation, H2 2011
Vernalis plc, H2 2011
Merck KGaA, H2 2011
Bone Medical Limited, H2 2011
4SC AG, H2 2011
3SBio Inc., H2 2011
Addex Pharmaceuticals, H2 2011
EntreMed, Inc., H2 2011
Evotec Aktiengesellschaft, H2 2011
Genesis Research and Development Corporation Ltd., H2 2011
GW Pharmaceuticals plc, H2 2011
Hollis-Eden Pharmaceuticals, Inc., H2 2011
Active Biotech AB, H2 2011
IMMUNOMEDICS, INC, H2 2011
Can-Fite BioPharma Ltd., H2 2011
Idera Pharmaceuticals, Inc., H2 2011
Karo Bio, H2 2011
Almirall, S.A., H2 2011
Lupin Limited, H2 2011
Medivir AB, H2 2011
Nutra Pharma Corporation, H2 2011
Compugen Ltd., H2 2011
Lexicon Pharmaceuticals, Inc., H2 2011
Accentia Biopharmaceuticals, Inc., H2 2011
Portola Pharmaceuticals, Inc., H2 2011
Chelsea Therapeutics, Inc., H2 2011
CombinatoRx, Incorporated, H2 2011
CSL Limited, H2 2011
Yuhan Corporation, H2 2011
Regeneron Pharmaceuticals, Inc., H2 2011
Protalix BioTherapeutics, Inc., H2 2011
Tolerx, Inc., H2 2011
XOMA Ltd., H2 2011
Antisoma plc, H2 2011
MorphoSys AG, H2 2011
Boryung Pharmaceutical Co., Ltd., H2 2011
Green Cross Corporation, H2 2011
Hanall Pharmaceutical Co., Ltd., H2 2011
Cytos Biotechnology AG, H2 2011
LG Life Sciences, Ltd, H2 2011
AnGes MG, Inc., H2 2011
Biotie Therapies Corp., H2 2011
Transition Therapeutics Inc., H2 2011
LTT Bio-Pharma Co., Ltd., H2 2011
Galapagos NV, H2 2011
Synta Pharmaceuticals Corp., H2 2011
CrystalGenomics, Inc., H2 2011
Sareum Holdings plc, H2 2011
Protalex, Inc., H2 2011
Proximagen Neuroscience plc., H2 2011
Newron Pharmaceuticals S.p.A., H2 2011
DiaMedica Inc., H2 2011
Simcere Pharmaceutical Group, H2 2011
Piramal Life Sciences Limited, H2 2011
Chroma Therapeutics Ltd., H2 2011
Affimed Therapeutics AG, H2 2011
AnaMar Medical AB, H2 2011
Viron Therapeutics, Inc., H2 2011
Immupharma Plc, H2 2011
Palau Pharma S.A, H2 2011
Philogen S.p.A., H2 2011
Probiodrug AG, H2 2011
Neovacs SA, H2 2011
MIKA Pharma GmbH, H2 2011
CREABILIS Therapeutics S.r.l., H2 2011
MAT Biopharma, H2 2011
Artielle ImmunoTherapeutics, Inc., H2 2011
Aquinox Pharmaceuticals Inc., H2 2011
InCode BioPharmaceutics, Inc., H2 2011
Amura Holdings Ltd., H2 2011
JADO Technologies GmbH., H2 2011
AnaptysBio, Inc., H2 2011
IMMD Inc., H2 2011
Circassia Holdings Ltd., H2 2011
Funxional Therapeutics Ltd, H2 2011
Oxagen Limited, H2 2011
Recoly N.V., H2 2011
Opsona Therapeutics Ltd., H2 2011
Asahi Kasei Pharma, H2 2011
Vaccinex, Inc., H2 2011
Syntrix Biosystems, Inc., H2 2011
Peptimmune, Inc., H2 2011
S-BIO Pte Ltd, H2 2011
Deciphera Pharmaceuticals, LLC, H2 2011
Indus Biotech Private Limited, H2 2011
NovImmune SA, H2 2011
Txcell SA, H2 2011
Theraclone Sciences, Inc., H2 2011
Theracos, Inc., H2 2011
TcL Pharma SAS, H2 2011
Versartis, Inc., H2 2011
Virobay Inc., H2 2011
Myriad Pharmaceuticals, Inc., H2 2011
Inimex Pharmaceuticals, Inc., H2 2011
Karus Therapeutics Ltd, H2 2011
Logical Therapeutics, Inc., H2 2011
Omeros Corporation, H2 2011
Xencor, Inc., H2 2011
BioStar Pharmaceuticals, Inc., H2 2011
Cornerstone Therapeutics Inc., H2 2011
Acetylon Pharmaceuticals, Inc., H2 2011
Trillium Therapeutics Inc., H2 2011
ChemoCentryx, Inc., H2 2011
CBio Limited, H2 2011
VentiRx Pharmaceuticals, Inc., H2 2011
KaloBios Pharmaceuticals, Inc., H2 2011
Action Pharma A/S, H2 2011
AB Science, H2 2011
Resolvyx Pharmaceuticals, Inc, H2 2011
Cellerix, S.A., H2 2011
Phytomedics, Inc., H2 2011
Avesthagen Limited, H2 2011
Nuon Therapeutics, Inc., H2 2011
KAHR medical Ltd., H2 2011
Viromed Co., Ltd., H2 2011
Ferring Pharmaceuticals, Inc., H2 2011
Centocor Ortho Biotech, Inc., H2 2011
Aphoenix, Inc., H2 2011
Advanced Cancer Therapeutics, H2 2011
Domainex Ltd., H2 2011
Cellceutix Pharmaceuticals, Inc., H2 2011
Dynamix Pharmaceuticals Ltd., H2 2011
Lycera Corp., H2 2011
OHR Pharmaceutical Inc., H2 2011
Femta Pharmaceuticals, Inc., H2 2011
UCB S.A., H2 2011
Mycenax Biotech Inc., H2 2011
Cellmid Ltd, H2 2011
Mebiopharm Co., Ltd., H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Rheumatoid Arthritis Therapeutics – Drug Profile Updates
Discontinued Products

List of Figures
Number of Products under Development for Rheumatoid Arthritis, H2 2011
Products under Development for Rheumatoid Arthritis – Comparative Analysis, H2 2011
Products under Development by Companies, H2 2011
Products under Investigation by Universities/Institutes, H2 2011
Late Stage Products, H2 2011
Mid Clinical Stage Products, H2 2011
Early Clinical Stage Products, H2 2011
Discovery and Pre-Clinical Stage Products, H2 2011
Assessment by Monotherapy Products, H2 2011
Assessment by Combination Products, H2 2011
Assessment by Route of Administration, H2 2011
Assessment by Stage and Route of Administration, H2 2011
Assessment by Molecule Type, H2 2011
Assessment by Stage and Molecule Type, H2 2011

Customers who bought this item also bought

• Rheumatoid Arthritis - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2012
• Acute Pain - Pipeline Review, H2 2012
• Autoimmune Disorders - Pipeline Review, H2 2012
• Male Cancer - Pipeline Review, H2 2012
• Type 2 Diabetes - Pipeline Review, H2 2012
• Hepatitis - Pipeline Review, H2 2012
• Alzheimer's Disease - Pipeline Review, H2 2012
• Obesity - Pipeline Review, H2 2012
• Psoriasis - Pipeline Review, H2 2011